MolecuLight

Focus: MolecuLight is a public-stage biotechnology company headquartered in Toronto specializing in fluorescence imaging devices for detecting wound infections and monitoring healing outcomes. The company focuses on point-of-care diagnostic solutions in the wound care market.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About MolecuLight

AI assessmentNot Hiring

No open roles listed right now. Follow MolecuLight to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

11 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

MolecuLight i:X Imaging Device

Wound infection detection and monitoring

Growth

Flagship fluorescence imaging platform deployed across multiple wound indications including diabetic foot ulcers and graft failure monitoring.

MolecuLight DX Imaging Device

Wound infection and wound assessment

Help build intelligence for MolecuLight

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused portfolio on high-unmet-need wound care market with 11 active clinical programs targeting diabetic foot ulcers, graft failure, and infection detection
Public company status provides equity upside potential and established capital markets access for growth funding
Proprietary fluorescence imaging technology platform (MolecuLight i:X and DX devices) enables differentiation in fragmented wound diagnostics space

Watch Out For

Zero current job openings signal potential organizational stability challenges or limited hiring momentum despite public status
Limited financial and operational transparency in available data (no revenue, R&D spend, or employee count disclosed) makes career stability assessment difficult

Generated by Claude from MolecuLight's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Next-generation diagnostic imaging device targeting point-of-care wound infection detection and clinical decision support.

Pipeline & Clinical Trials

MolecuLight PID

Wound

N/A

Clinical Trials (1)

NCT03967405A Prospective Evaluation of Clinical Equivalence Between iX and PID

N/A

MolecuLight DX Imaging Device

Wound Infection

N/A

Clinical Trials (1)

NCT05196880Biofilm Correlation and Validation

N/A

imaging, no intervention

Wounds and Injuries

N/A

Clinical Trials (1)

NCT03091361Post Market Clinical Followup of MolecuLight i:X's PPV to Predict Presence of Bacteria in Wounds

N/A

Fluorescence Imaging Device

Wound

N/A

Clinical Trials (1)

NCT03754426A Prospective, Pilot Evaluation of Device Equivalence

N/A

MolecuLight DX Imaging Device

Wounds

N/A

Clinical Trials (1)

NCT06682923MolecuLightDX Measurement Feature Clinical Validation

N/A

Positive Predictive Value (PPV) of Pseudomonas Aeruginosa

Wound

N/A

Clinical Trials (1)

NCT03290690Positive Predictive Value (PPV) of Pseudomonas Aeruginosa

N/A

MolecuLight i:X Imaging Device

Wound

N/A

Clinical Trials (1)

NCT03540004Evaluation of MolecuLight i:X as an Adjunctive Fluorescence Imaging Tool to Clinical Signs and Symptoms for the Identification of Bacteria-containing Wounds

N/A

MolecuLight i:X Imaging Device

Non Healing Diabetic Foot Ulcer

N/A

Clinical Trials (1)

NCT04207099Comparing Wound Area Reduction of Non-healing DFUs Using MolecuLight i:X Versus Standard of Care

N/A

Point-spectroscopy Trial

Wound

N/A

Clinical Trials (1)

NCT05183698Point-spectroscopy Trial

N/A

MolecuLight i:X Imaging Device

Wounds

N/A

Clinical Trials (1)

NCT02682069Positive Predictive Value of the MolecuLight i:X Imaging Device to Predict the Presence of Bacteria in Chronic Wounds

N/A

MolecuLight i:X imaging

Skin Graft (Allograft)(Autograft) Failure

N/A

Clinical Trials (1)

NCT04185636Presence of Fluorescence Signature to Predict Graft Failure Using MolecuLight i:X

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 11 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo